UNSPSC 51351617: Methylestrenolone

This classification denotes a progesterone congener with the molecular formula C19H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 743F1Z557A, chemically known as 17alpha-Methyl-19-nortestosterone but generally known as Methylestrenolone, which bears US NIH Compound Identifier 5284597. European Medicines Agency schedules Methylestrenolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14667MIG. SMILES: CC12CCC3C(C1CCC2(C)O)CCC4=CC(=O)CCC34.

UNSPSC 51351617 Methylestrenolone is a Commodity code covering anabolic and androgenic steroid pharmaceuticals. State and local government procurement under this code centers on generic multi-source pharmaceutical sourcing through cooperative purchasing agreements that distribute products across state agencies, local government facilities, schools, and health systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body in recent activity, procuring pharmaceuticals through established manufacturer relationships with mandatory distribution via authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Vendors must hold current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers with chargeback systems in place, and carry commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. Pricing evaluation emphasizes price competitiveness (75 percent weight) alongside administrative compliance, EDI capability, and agreement to a 3 percent administrative fee, with performance penalties ranging from $200 to $1,500 per violation for reporting delays or onboarding failures.

MMCAP's recent RFP (Solicitation S1070000015802, due March 26, 2026) reflects cooperative purchasing across multiple states including Minnesota and Oregon. The contract term extends two years for new responders with optional extensions at MMCAP's discretion, while incumbent vendors' amendments align with existing agreement expiration through June 30, 2028. All products must meet FDA requirements, possess expiration dates of at least one year from manufacture with minimum six-month shelf life, and be available in the marketplace by May 15, 2026, when awarded vendor lists will be provided to wholesalers and agreements become effective July 1, 2026. Proposals require submission through the ePro procurement system with pricing and product information in designated Excel-to-CSV format, supported by documentation emailed to MMCAP_Infuse.RFP@state.mn.us, with a question cutoff of February 18, 2026.